Interventional Intracranial Aneurysm Devices Market to Surpass US$ 6,632.92 Mn by 2030

Global Interventional Intracranial Aneurysm Devices Market, by Procedure Type, (Aenurysm Coil Embolization, FD Placement, Overmolded Stent Carrying Artery Occlusion, Other Procedures (Surgical Clipping, etc.)), by Intracranial Aneurysm Type (Saccular Aneurysm, Fusiform Aneurysm, Others (Mycotic aneurysms, etc.)), by End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 3,670.34 million in 2022 and is expected to exhibit a CAGR of 7.7% during the forecast period (2022-2030).

Market players are launching product, in order to expand their product portfolio. This is expected to drive growth of the global interventional intracranial aneurysm devices market over the forecast period. For instance, in October, 2021, Evasc Neurovascular, a privately held medical device company, announced the launch of eCLIPs Bifurcation Flow Diverter, the third generation of their eCLIPs device. eCLIPs is a non-tubular endovascular device that uses technology to treat 95% of cases of bifurcation aneurysms and is currently intended for use in difficult wide-neck bifurcations.

Market players are adopting inorganic growth strategies such as collaboration, which is expected to drive the growth of global interventional intracranial aneurysm devices market over the forecast period. For instance, in August 2019, Fujitsu Australia & GE Healthcare – two medical technology companies, along with Macquarie University, and Macquarie Medical Imaging had launched a new research in collaboration to improve the diagnosis of brain aneurysms. The goal of the project is to create a tool that uses artificial intelligence (AI) to more quickly and effectively detect and track brain aneurysms on images.

Global Interventional Intracranial Aneurysm Devices Market - Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to hamper growth of the global interventional intracranial aneurysm devices market, over the forecast period. COVID-19 is the recent pandemic outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases are decreasing after September 18, 2022. Therefore, as of September 18, 2022, over 609 million confirmed cases and over 6.5 million deaths have been reported globally.

The health care industries had faced challenged in supply, distribution, and manufacturing of medical supplies globally during COVID-19 pandemic, which as hamper the growth of global interventional intracranial aneurysm devices market. For instance, according to data published on May 6, 2021, by National Center for Biotechnology Information, the global lockdown had negatively impacted the manufacturing industries and supplies of healthcare products, which is expected to hamper growth of the global interventional intracranial aneurysm devices market.

Browse 31 Market Data Tables and 41 Figures spread through 406 Pages and in-depth TOC on global interventional intracranial aneurysm devices market, by Procedure Type, (Aenurysm Coil Embolization, FD Placement, Overmolded Stent Carrying Artery Occlusion, Other Procedures (Surgical Clipping, etc.)), by Intracranial Aneurysm Type (Saccular Aneurysm, Fusiform Aneurysm, Others (Mycotic aneurysms, etc.)), by End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the interventional intracranial aneurysm devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/interventional-intracranial-aneurysm-devices-market-5271

Market players are engaged in inorganic growth strategies such as agreements to expand the sales of their product, and this is expected to boost the growth of global interventional intracranial aneurysm devices market over forecast period. For instance, in July 2021, Kaneka Corporation, a Japan-based worldwide chemical manufacturing company, announced a sales agreement with Asahi Intecc USA, Inc., a medical technology manufacturer, to further increase the sales of its novel brain aneurysm embolization coil (product name: i-ED COIL) in the U.S. market.

Key Takeaways of the Global Interventional Intracranial Aneurysm Devices Market:

• The global interventional intracranial aneurysm devices market is expected to exhibit a CAGR of 7.7% over the forecast period (2022-2030), owing to growth in potential markets, especially in North America. While Europe accounted for the major market share.
• Increasing regulatory approvals for interventional intracranial aneurysm treatment devices, is expected to drive the growth of global interventional intracranial aneurysm devices market over the forecast period. For instance, in January 2021, MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced that the U.S. Food and Drug Administration (FDA) approved the Premarket approval (PMA) Supplement for its WEB 17 System to treat intracranial broad neck bifurcation aneurysms.
• Major players operating in the global interventional intracranial aneurysm devices market include MicroPort Scientific Corporation, B. Braun SE, Stryker, MicroVention Inc., Johnson & Johnson Private Limited, Terumo Corporation, Penumbra, Inc., KANEKA CORPORATION, Perflow Medical Ltd, phenox GmbH, Evasc, ASAHI INTECC CO., LTD., Acandis GmbH, Imperative Care, and Medtronic.